China Healthcare: Macro Themes
451 Views18 Dec 2020 20:56
This Insight summarizes the takeaways from a recent China healthcare industry conference. There is much talk of pressures on the industry, but innovative companies will benefit from policy tailwinds.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
- BeiGene: Novartis Grabs Tislelizumab Rights13 Jan 2021
- BeiGene: Cancer Treatment in China--The Underestimated Opportunity10 Jan 2021
- Microport Cardioflow: Winning in TAVR10 Jan 2021
- China Healthcare: Macro Themes18 Dec 2020
- Eddingpharm: First Impressions15 Dec 2020
- Jacobio: Updated Valuation and Other Thoughts04 Dec 2020
- Asian Healthcare - Coming of Age26 Nov 2020
x